JP2004532900A5 - - Google Patents

Download PDF

Info

Publication number
JP2004532900A5
JP2004532900A5 JP2003510677A JP2003510677A JP2004532900A5 JP 2004532900 A5 JP2004532900 A5 JP 2004532900A5 JP 2003510677 A JP2003510677 A JP 2003510677A JP 2003510677 A JP2003510677 A JP 2003510677A JP 2004532900 A5 JP2004532900 A5 JP 2004532900A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid molecule
disease
diaminopurine
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003510677A
Other languages
English (en)
Japanese (ja)
Other versions
JP4903984B2 (ja
JP2004532900A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2002/001046 external-priority patent/WO2003004511A2/en
Publication of JP2004532900A publication Critical patent/JP2004532900A/ja
Publication of JP2004532900A5 publication Critical patent/JP2004532900A5/ja
Application granted granted Critical
Publication of JP4903984B2 publication Critical patent/JP4903984B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003510677A 2001-07-06 2002-07-08 オリゴヌクレオチドのinvivoでの効率を増加するおよび哺乳動物において炎症を阻害するための方法 Expired - Fee Related JP4903984B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30307101P 2001-07-06 2001-07-06
US60/303,071 2001-07-06
PCT/CA2002/001046 WO2003004511A2 (en) 2001-07-06 2002-07-08 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals

Publications (3)

Publication Number Publication Date
JP2004532900A JP2004532900A (ja) 2004-10-28
JP2004532900A5 true JP2004532900A5 (cg-RX-API-DMAC7.html) 2006-01-05
JP4903984B2 JP4903984B2 (ja) 2012-03-28

Family

ID=23170407

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003510677A Expired - Fee Related JP4903984B2 (ja) 2001-07-06 2002-07-08 オリゴヌクレオチドのinvivoでの効率を増加するおよび哺乳動物において炎症を阻害するための方法

Country Status (13)

Country Link
US (2) US7745420B2 (cg-RX-API-DMAC7.html)
EP (1) EP1406667B1 (cg-RX-API-DMAC7.html)
JP (1) JP4903984B2 (cg-RX-API-DMAC7.html)
AT (1) ATE386548T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002319033B2 (cg-RX-API-DMAC7.html)
CA (1) CA2451738C (cg-RX-API-DMAC7.html)
DE (1) DE60225141T2 (cg-RX-API-DMAC7.html)
DK (1) DK1406667T3 (cg-RX-API-DMAC7.html)
ES (1) ES2301659T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA04000162A (cg-RX-API-DMAC7.html)
NZ (1) NZ530360A (cg-RX-API-DMAC7.html)
PT (1) PT1406667E (cg-RX-API-DMAC7.html)
WO (1) WO2003004511A2 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007005083A (es) * 2004-10-29 2007-10-03 Topigen Pharmaceuticals Inc Oligonucleotidos antisentido para tratar alergias y proliferacion celular neoplastica.
JP6047270B2 (ja) 2006-08-11 2016-12-21 バイオマリン テクノロジーズ ベー.フェー. Dnaリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
NZ584793A (en) 2007-10-26 2012-05-25 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
EP2285961A4 (en) * 2008-05-15 2012-10-17 Topigen Pharmaceuticals Inc OLIGONUCLEOTIDES FOR THE TREATMENT OF INFLAMMATION AND NEOPLASTIC CELL REPRODUCTION
WO2010048731A1 (en) * 2008-10-31 2010-05-06 Christopher John Ong Aminoacyl trna-synthetase inhibitors as broad-spectrum immunosuppressive agents
US9622909B2 (en) 2009-02-26 2017-04-18 Advanced Cooling Therapy, Inc. Devices and methods for controlling patient temperature
PL2401023T3 (pl) * 2009-02-26 2016-12-30 Urządzenie do sterowania temperaturą pacjenta
US9301871B2 (en) 2009-02-26 2016-04-05 Advanced Cooling Therapy, Inc. Devices and methods for controlling patient temperature
US9326890B2 (en) 2009-02-26 2016-05-03 Advanced Cooling Therapy, Inc. Devices and methods for controlling patient temperature
JP2014511181A (ja) * 2011-02-24 2014-05-15 ファーマキシス リミテッド キメラ骨格および2−アミノ−2’−デオキシアデノシンを有するオリゴヌクレオチド阻害剤
CA2862628C (en) * 2012-01-27 2021-08-24 Prosensa Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
US9272016B2 (en) * 2012-04-20 2016-03-01 University Of Iowa Research Foundation Methods to enhance RNAi oligonucleotide delivery to respiratory epithelial cells
PT2841578T (pt) * 2012-04-23 2017-08-10 Biomarin Tech Bv Resumo
FR3057774B1 (fr) * 2016-10-21 2025-11-07 Museum Nat Dhistoire Naturelle Derives de la purine pour leur utilisation dans le traitement ou la prevention de maladies dues a une mutation non-sens

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3337530A (en) * 1965-09-20 1967-08-22 Upjohn Co Dinucleoside 3', 5' -and 2', 5'-phosphates containing one 7-deazapurin riboside moiety
JPH01173818A (ja) * 1987-12-28 1989-07-10 Aisin Aw Co Ltd 車両用ナビゲーション装置
US5523205A (en) * 1988-08-02 1996-06-04 Institut Pasteur DNA probes specific for hemolytic listeria
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5112961A (en) * 1990-07-18 1992-05-12 Schering Corporation Dna encoding subunits of a high affinity gm-csf receptor
EP0509826A1 (en) * 1991-04-19 1992-10-21 Schering Corporation Subunit of the human interleukin 3 receptor
US5872242A (en) 1992-10-05 1999-02-16 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of ras
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US6077668A (en) * 1993-04-15 2000-06-20 University Of Rochester Highly sensitive multimeric nucleic acid probes
CA2235420A1 (en) 1998-06-17 1999-12-17 Paolo Renzi Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
ATE346918T1 (de) * 1998-06-19 2006-12-15 Univ Mcgill Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide
HK1042706A1 (zh) * 1998-08-03 2002-08-23 东卡罗来纳大学 低腺苷反义寡核苷酸制剂、组合物、试剂盒及处理
US6175004B1 (en) * 1998-09-01 2001-01-16 Isis Pharmaceuticals, Inc. Process for the synthesis of oligonucleotides incorporating 2-aminoadenosine
AU4031700A (en) 1999-04-06 2000-11-02 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation,allergy(ies) and surfactant depletion

Similar Documents

Publication Publication Date Title
US20100286235A1 (en) Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals
CN105873902B (zh) 用于rna递送的可电离的阳离子脂质
CN109689672B (zh) 用于rna病毒治疗的2’-取代的-n6-取代的嘌呤核苷酸
JP2024071397A5 (cg-RX-API-DMAC7.html)
US10227302B2 (en) Ionizable cationic lipid for RNA delivery
US7427606B2 (en) Method to reduce inflammatory response in transplanted tissue
JP2003530322A (ja) 抗ウイルス性プロドラッグ
JP2001513568A (ja) 肺疾患を治療するためのウリジン5’−ジホスフェートとその類似体の使用
JP2002540160A (ja) プロトン化/酸性化核酸の肺輸送
WO1998023294A9 (en) Agent and method of treatment for diseases and conditions associated with respiratory ailments and lung inflammation
JP2001510484A (ja) ジ(ウリジン5’)−テトラホスフェート及びその塩の大規模生産のための方法
EP0946201A1 (en) Agent and method of treatment for diseases and conditions associated with respiratory ailments and lung inflammation
AU2002319033A1 (en) Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals
TW202340466A (zh) 一種dsrna、其製備方法及應用
TW201919654A (zh) 用於抑制α-ENaC表現之RNAi試劑及使用方法
US20150329864A1 (en) Design of oligonucleotide analogs as therapeutic agents
WO1999063938A2 (en) Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs
TW593331B (en) Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
TW202130809A (zh) 用於抑制β-ENaC表現之RNAi藥劑、其組合物及使用方法
TW202412845A (zh) 用於遞送治療劑至cns組織之脂質結合物
JP2002515892A (ja) サイトカインが関係する疾患治療法
JP2021500903A5 (cg-RX-API-DMAC7.html)
TW202339773A (zh) 一種dsRNA、其應用及製備方法
JP2025509552A (ja) 修飾ギャップマーオリゴマー及びその使用方法
CN117440817A (zh) 用于抑制晚期糖基化终末产物受体表达的RNAi剂、其组合物和使用方法